NKp46/NCR1/CD335, His, Human
| $390.00 | |
| Z05694-100 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
IVD Raw Materials
| $390.00 | |
| Z05694-100 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by BisTris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 27.5 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 38-48 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
Immobilized NKp46/NCR1/CD335, His, Human, His Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-Nkp46 Antibody, hFc Tag with the EC50 of 11.2ng/ml determined by ELISA. »
The purity of NKp46/NCR1/CD335, His, Human is greater than 95% as determined by SEC-HPLC. »
NKp46/NCR1/CD335, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | NKp46, along with NKp30 and NKp44, are activating receptors that have been collectively termed the natural cytotoxicity receptors (NCR). These receptors lack significant sequence homology to one another. They are expressed almost exclusively by NK cells and play a major role in triggering some of the key lytic activities of NK cells. |
| Synonyms | CD335; Ly94; NCR1; NKp46; MAR-1; NKP46FLJ99094 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.